NSE: AUROPHARMA · Healthcare · Pharmaceuticals · Market cap ₹1,06,750 Cr
· Prev close ₹1,804.00 · Volume 24.12 L · 52W ₹1,106–1,855
Day range for 9 Nov not in the price history yet · 8 Nov ₹1,798.10–1,816.10
Last 4 quarters: profit +16.6% on the 4 beforeShare price +9.7% in a month
If profit compounds at 7.3% (CAGR) and the stock ends at 25×, buying at ₹1,855 returns about 6.5% CAGR over 10 years.
| Growth assumption | Profit growth (CAGR) | Return, 10Y CAGR |
|---|---|---|
| Yours | 7.3% | 6.5% |
| Delivered FY22–26 | 7.3% | 6.5% |
| Net profit, last 4 quarters vs the 4 before | 16.6% | 15.7% |
| Half the delivered pace | 3.6% | 2.9% |
Delivered FY22–26 CAGR 7.3%
This is an exit-multiple calculation, not a discounted cash flow. Inputs: EPS for the 4 quarters Dec 2025 to Sep 2026 ₹68.96, price ₹1,855.30 (9 Nov 2026, 3:50 pm IST price). Formula: return = (EPS × exit P/E ÷ price)^(1/10) × (1 + growth) − 1. Net profit growth is applied to EPS, so the share count is held constant. A profit fall of 100% or more has no rate and is left blank. Dividends ignored. Arithmetic, not a forecast.